EU Regulation 2021/2226 and FDA guidance allow eIFUs for specified professional-use device categories, subject to risk assessment, accessibility, and the right of users to request a paper copy. In the EU, Commission Implementing Regulation (EU) 2021/2226 allows electronic instructions for use only for certain professional-use devices, such as implantables, fixed installed devices and devices with built-in IFU displays, provided a risk assessment is done and paper copies are available on request. In the US, FDA permits electronic labeling for certain prescription devices and IVDs. Websites hosting eIFUs must stay accessible and version-controlled.

Why it matters

eIFUs reduce environmental impact and enable rapid updates, but require version control, archived prior versions, and reliable hosting infrastructure.

Common pitfalls

•Failing to conduct a comprehensive risk assessment for the eIFU system can lead to non-compliance and potential patient harm.
•Neglecting to provide users with a clear and easily accessible option to request a paper copy of the IFU is a common pitfall.
•Inadequate version control or an unreliable hosting infrastructure for eIFUs can result in the use of outdated or incorrect information.
•Assuming all device categories are eligible for eIFU, without verifying specific regulatory allowances, can lead to significant regulatory issues.
•Not considering the accessibility needs of all users, including those with disabilities, in the design of the eIFU system is a frequent oversight.

Sources

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.